Market Newsdesk

Achieving substantial improvements in customer experience and servicing oversight costs

Cutera Directors J. Daniel Plants and David Mowry Respond to Special Committee’s Attempt to Rewrite History

Clarify What This Campaign is About and What it is Not

Cite Recent Value-Destructive Actions of the Special Committee as Further Support for Reconstituting the Board

Highlight Multiple False and Misleading Statements from the Special Committee

SAN FRANCISCO–(BUSINESS WIRE)–
Today J. Daniel Plants, Founder and Chief Investment Officer of Voce Capital Management LLC and a member of the Board of Directors (the “Board”) of Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), and David Mowry, also a Cutera Director – who together own approximately 7.0% of the outstanding shares of Cutera – issued the following statement in response to a recent press release from the Special Committee of Cutera’s Board:

“The events of the past week, particularly the wrongful termination of our roles as Executive Chairman and CEO, respectively, have only further solidified the need for meaningful Board change at Cutera. The press release issued yesterday by Gregory Barrett, Sheila Hopkins, Timothy O’Shea, Juliane Park and Janet Widmann (the “Entrenched Directors”) contains numerous misleading, incomplete and untrue statements. The Entrenched Directors’ revisionist history is contradicted by the actual decisions they made and actions they carried out. The below seeks to rectify what we believe are the many omissions and falsehoods visited upon Cutera’s stakeholders by the Special Committee:

• The CEO succession process was, and is, deeply flawed. What the Entrenched Directors left out of yesterday’s release speaks volumes. As of April 11, when the Entrenched Directors removed Mr. Plants from the CEO Search Committee, in its seven weeks of existence, the CEO Search Committee had not met a single time. All of the progress the Entrenched Directors cite in their release occurred after Mr. Plants sent a private letter to the Board on April 3 expressing concerns over the lack of advancement on the external CEO search. In our view, the statement in the release that no member of the Entrenched Directors has ever sought a permanent executive role at Cutera is also highly misleading. As was revealed during the February 22, 2023 Board meeting referenced by the Entrenched Directors, Mses. Hopkins, Park and Widmann all expressed interest in becoming Cutera’s CEO and, from our perspective, the resulting conflicts of interest tainted all of the Board decisions in which they participated.

  The bottom line is that even if one accepts as true, the Entrenched Directors’ statement that they had made a firm decision to replace Mr. Mowry in November 2022, five full months have now passed and they have nothing to show for their efforts. That is prima facie evidence of their dysfunction and ineffective stewardship of the process, in our opinion. Further, as the April 3 letter from Mr. Plants to the other members of the Board makes clear, Messrs. Plants and Mowry’s efforts to make headway in the appointment of a new CEO were undermined by the Entrenched Directors’ attempted usurpation of critical decisions through private conclaves convened outside of proper Board and committee meetings.

  Any attempt by the Entrenched Directors to name a new CEO between now and the Special Meeting, when shareholders’ voices will be heard, would be presumptively invalid, in our view, and we do not believe that shareholders would accept the legitimacy of such a move or support anyone appointed in this manner when the voting occurs at the Special Meeting and/or Annual Meeting.

• Our campaign is not about Mr. Plants becoming CEO of Cutera. Mr. Plants officially removed his name from consideration to become the Company’s next CEO during the February 22, 2023 Board meeting. It is disingenuous to say the Board merely considered his interest in the job. While it is true that ultimately the Board and Mr. Plants could not come to terms prior to him withdrawing from the process, the Entrenched Directors’ release conveniently omits that the Board formally offered Mr. Plants the CEO job on multiple occasions; when that effort failed, the Board then offered him the interim CEO role several times, each of which he declined. There is also no mention of the fact that Mr. Plants had the full endorsement of Mr. Mowry throughout this process. These facts refute any notion that the Board decided Mr. Plants was somehow unfit for the job, as implied by their misleading statements. Mr. Plants’ willingness to walk away from the Board’s numerous offers of employment as CEO also belies the allegation that he somehow desired to take ‘control’ of the Company.

  Mr. Plants is employed full-time at Voce Capital Management LLC, the SEC-registered investment adviser he founded in 2011. His present efforts at Cutera are directed toward protecting his investment in the Company as one of its largest shareholders. Both he and Mr. Mowry believe that Mr. Mowry should be reappointed as CEO and remain on the Board, and only then should an orderly CEO succession process to identify an external candidate be conducted with the benefit of Mr. Mowry’s experience and detailed knowledge of the Company. Joseph Whitters, an independent director of the Company who is not aligned with the Entrenched Directors, recently issued his own press release expressing his opinion that Mr. Mowry should remain as CEO, and Mr. Plants as Executive Chairman, through this transition. Shareholders should also know that Mr. Plants had already communicated several weeks ago his intention to relinquish the ‘Executive’ title upon the hiring of Mr. Mowry’s successor.

• The Board’s harsh criticisms now of Mr. Mowry’s 2022 performance ring hollow. The Board never conducted a 2022 performance review for Mr. Mowry. Moreover, as part of the transition triggered by his decision to retire, as he communicated on January 4, 2023, the Board agreed on February 7 to a written, 12-month consulting agreement whereby Mr. Mowry would remain on the Board, assume responsibility for a variety of specified projects, maintain the same base compensation level and continue to vest in his equity. It strains credibility for the Special Committee to now imply that Mr. Mowry’s performance was so deficient that he needed to immediately depart or that Mr. Plants sought Mr. Mowry’s ‘immediate termination’ from the Company when, in fact, everyone (including Mr. Plants) wanted him to remain in place for an extended period of time to ensure the smoothest transition possible.

• The recent value-destructive actions of the Entrenched Directors underscore the need for change. Instead of engaging in constructive private discussions with Messrs. Plants and Mowry privately regarding their concerns, as both Messrs. Plants and Mowry made clear was their desire, the Entrenched Directors decided to escalate the disagreements by issuing a press release on April 7. Then on April 11, the Entrenched Directors seized full control of the Company, deciding (with only the conflicted Entrenched Directors voting in favor) to oust Mr. Plants as Chairman, terminate his employment as Executive Chairman, and to fire Mr. Mowry as CEO. The Board took all these actions despite the fact that Pura Vida Investments, LLC – an approximately 7% shareholder – earlier that same day had publicly called on the Board to resolve its disagreement with the CEO and Chairman and not to make any changes, in order to secure an orderly succession process and protect shareholder value.

  The market reaction to the Entrenched Directors’ coup speaks for itself – the Company’s stock price fell nearly 30% at market open the following day, one of its worst trading days since its 2004 IPO. On April 12, 2023, RTW Investments, LP, an approximately 9.3% shareholder of Cutera, publicly expressed its concern about the events that had transpired at the Company and asserted that ‘the market reaction to the removal of Mr. Mowry as CEO demonstrates…the lack of confidence in the Board.’¹

• Shareholders should ask themselves who they trust to steward their investment in Cutera and shepherd the Company through this critical point in its evolution. On one side of this debate you have Messrs. Mowry, Plants and Whitters. Messrs. Mowry and Plants have the deepest knowledge of, and involvement in, the Company of anyone on the Board; Mr. Whitters is the Board’s only qualified financial expert. The AviClear commercial strategy, which the Entrenched Directors now trumpet, was developed by Messrs. Plants and Mowry. In terms of judgment and experience, Mr. Whitters has served on the Boards of eight public companies (not including Cutera) and has been elected chairman of three. Not coincidentally, these are the three largest shareholders on the Board and collectively dwarf the aggregate holdings of the Entrenched Directors.

  On the other side are five directors with what we consider to be de minimis stock ownership. Three of these individuals have never made one open market purchase of shares, despite their Board appointments having been conditioned upon doing so; and a fourth member purchased a grand total of 500 shares over the course of his 19 years on the Board. In our view, they have little more than an academic interest in the outcome of the critical decisions facing the Company.

Each of us called, and fought for, a Special Meeting of Shareholders so that the voices of our fellow owners could be heard, especially before the Board makes the important decision as to who will be the Company’s next CEO. The Special Meeting will occur on June 9, 2023. We will continue to communicate as we approach the Special Meeting, and we encourage all of Cutera’s stakeholders to scrutinize carefully the ongoing diet of claims, allegations and base innuendo propagated by the Entrenched Directors. As we have always done, we commit to pursue the well-being of the Company for the benefit of all stakeholders, including the restoration of sound corporate governance and resolution of the needless crisis that the Entrenched Directors have willfully plunged the Company into.”

Forward-Looking Statements and Third-Party Statements

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in any state to any person. This press release does not recommend the purchase or sale of a security. There is no assurance or guarantee with respect to the prices at which any securities of the Company will trade, and such securities may not trade at prices that may be implied herein. In addition, this press release and the discussions and opinions herein are for general information only, and are not intended to provide investment advice.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, “will be” and similar expressions. Although Voce Capital Management LLC (“Voce Capital Management”) believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties—many of which are difficult to predict and are generally beyond the control of Voce Capital Management or the Company—that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties are enumerated in the Company’s public filings. In addition, the foregoing considerations and any other publicly stated risks and uncertainties should be read in conjunction with the risks and cautionary statements discussed or identified in the Company’s public filings with the United States Securities and Exchange Commission (the “SEC”), including those listed under “Risk Factors” in the Company’s annual reports on Form 10-K and quarterly reports on Form 10-Q. The forward-looking statements speak only as of the date hereof and, other than as required by applicable law, Voce Capital Management does not undertake any obligation to update or revise any forward-looking information or statements.

Funds managed by Voce Capital Management currently beneficially own shares of the Company. These funds are in the business of trading (i.e., buying and selling) securities and intend to continue trading in the securities of the Company. You should assume such funds will from time to time sell all or a portion of their holdings of the Company in open market transactions or otherwise, buy additional shares (in open market or privately negotiated transactions or otherwise), or trade in options, puts, calls, swaps or other derivative instruments relating to such shares.

Consequently, Voce Capital Management’s beneficial ownership of shares of, and/or economic interest in, the Company may vary over time depending on various factors, with or without regard to Voce Capital Management’s views of the Company’s business, prospects, or valuation (including the market price of the Company’s shares), including, without limitation, other investment opportunities available to Voce Capital Management, concentration of positions in the portfolios managed by Voce Capital Management, conditions in the securities markets and general economic and industry conditions. Voce Capital Management also reserves the right to change the opinions expressed herein and its intentions with respect to its investment in the Company, and to take any actions with respect to its investment in the Company as it may deem appropriate, and disclaims any obligation to notify the market or any other party of any such changes or actions, except as required by law.

Voce Capital Management has not sought or obtained consent from any third party to use any statements or information indicated herein as having been obtained or derived from statements made or published by third parties.

CERTAIN INFORMATION REGARDING THE PARTICIPANTS

The Voce Parties (as defined below), together with the other Participants (as defined below), intend to file a proxy statement and accompanying proxy card with the SEC to be used to solicit votes in connection with (i) a special meeting of stockholders of Cutera, Inc. (the “Company”) for the purpose of supporting proposals to remove and replace certain members of the Company’s Board of Directors and/or (ii) seeking the election of nominees to the Board of Directors at the Company’s 2023 annual meeting of stockholders.

THE PARTICIPANTS STRONGLY ADVISE ALL STOCKHOLDERS OF THE COMPANY TO READ THE DEFINITIVE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC’S WEBSITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST.

The Participants in the solicitation are anticipated to be: (i) Voce Capital Management LLC, a California limited liability company (“Voce Capital Management”); (ii) Voce Catalyst Partners LP, a Delaware limited partnership (“Voce Catalyst Partners”); (iii) Voce Capital LLC, a Delaware limited liability company (“Voce Capital”); (iv) J. Daniel Plants, sole Managing Member of Voce Capital and a United States citizen (“Mr. Plants,” and together with Voce Capital Management and Voce Catalyst Partners, the “Voce Parties”); and (v) David H. Mowry, a United States citizen (“Mr. Mowry,” and together with the Voce Parties, the “Participants”).

As of the date hereof, the Participants may be deemed to beneficially own (within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934), in the aggregate, 1,483,632 shares of common stock, par value $0.001 per share, of the Company (the “Common Shares”). Of the 1,483,632 Common Shares beneficially owned in the aggregate by the Participants, including the 100 Common Shares owned by Voce Catalyst Partners in record name, such Common Shares may be deemed to be beneficially owned as follows: (a) 1,210,224 Common Shares may be deemed to be beneficially owned by Voce Capital Management, by virtue of it being the investment advisor to certain investment funds, including Voce Catalyst Partners; (b) 1,210,224 Common Shares may be deemed to be beneficially owned by Voce Capital, by virtue of it being the sole managing member of Voce Capital Management; (c) 1,274,844 Common Shares (including 2,724 Common Shares underlying unvested restricted stock units (“RSUs”) and 14,748 Common Shares underlying options) may be deemed to be beneficially owned by Mr. Plants by virtue of him being the Managing Partner of Voce Capital Management; and (d) 208,788 Common Shares may be deemed to be beneficially owned by Mr. Mowry (including 23,174 Common Shares underlying unvested RSUs and 59,823 Common Shares underlying options). In addition, Voce Capital Management previously entered into a purchase agreement with the Company for the purchase of $10 million in aggregate principal amount of the Company’s 2.25% Convertible Senior Notes due 2028.

Each of the Voce Parties expressly disclaims beneficial ownership of any Common Shares beneficially owned by Mr. Mowry. Mr. Mowry expressly disclaims beneficial ownership of any Common Shares beneficially owned by the Voce Parties.

__________________________

¹ Press Release: RTW Investments, LP Issues Statement Regarding Cutera’s Special Meeting of Stockholders. Permission to use quotation neither sought nor obtained.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230418006198/en/

Media Contact

Longacre Square Partners

Dan Zacchei / David Reingold

[email protected] / [email protected]

Investor Contact

D.F. King & Co., Inc.

Edward McCarthy

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Professional Services Health Medical Devices Finance

MEDIA:

Logo

Blackwells Capital Issues Letter to Shareholders of Global Net Lease, Inc (“GNL”) Ahead of Critical Vote at the 2023 Annual Meeting

Current Board has Failed Shareholders by Presiding Over Abysmal Financial Results, Industry-Worst Corporate Governance and the Plundering of Value by AR Global

Since GNL’s IPO in 2015, there have been 11 Dilutive Stock Offerings Totaling $662 Million. During the Same Period, AR Global has Collected $383 Million in Payments from GNL Shareholders. We Believe this Represents a Looting of Corporate Coffers of the Highest Order.

Urges Shareholders Vote on the WHITE Universal Proxy Card to Elect Blackwells’ Two Highly Qualified and Independent Director Candidates

NEW YORK–(BUSINESS WIRE)–
Blackwells Capital LLC (together with its affiliates “Blackwells” or “we”), today issued a letter to fellow shareholders regarding the urgent need for boardroom change at Global Net Lease, Inc. (NYSE: GNL) (“Global Net Lease” or “GNL”).

We invite all shareholders to learn more about our case for change and director candidates at www.StopARGlobal.com.

The full letter to shareholders has been reproduced below:

Dear fellow shareholder:

At the upcoming annual meeting of shareholders (including any other meeting of shareholders held in lieu thereof and adjournments, postponements, reschedulings or continuations thereof the “Annual Meeting”) on May 18, 2023, shareholders will have an opportunity to halt the ongoing destruction of value at Global Net Lease, Inc. (“Global Net Lease” or “GNL”) by electing two highly qualified and independent director candidates to hold AR Global Investments, LLC (“AR Global”) – the parent company of the ‘advisor’ and ‘property manager’ of GNL – accountable for what we believe is obvious self-dealing and self-enrichment.

We believe the case for boardroom change is clear based on the following:

• GNL trades at a 35% discount to its Net Asset Value and 51% discount to peers. This is due to the chokehold of its significantly off-market management agreement with AR Global. Since 2015, GNL has paid AR Global $383 million in fees and expenses while GNL shareholders have suffered a 64% stock price decline representing $2.1 billion in total value destruction.

• Since GNL’s initial public offering in 2015, there have been 11 dilutive stock issuances at the behest of AR Global. While shareholders have had to suffer through each of these dilutive issuances, AR Global’s unchecked parade against GNL’s coffers has led to annual fees and expenses increased 2.6x during the same period.

• We believe GNL’s Board of Directors (the “GNL Board”) and management are profoundly conflicted and have enabled AR Global’s self-dealing and corporate piracy. These entanglements include: (i) GNL CEO and Board member James L. Nelson, who holds a profit interest in GNL’s external advisor, which is owned by AR Global; (ii) GNL’s CFO, Chris Masterson, who is also CFO of another AR Global-managed REIT; (iii) Sue Perrotty, the GNL Board’s “lead independent director”, who should be acting as an independent fiduciary for GNL shareholders, yet has profited considerably as a director on the boards of several AR Global-managed REITs, and; (iv) Michael Weil, a GNL Board member who also sits as CEO of AR Global, the parent of GNL’s external advisor.

• Blackwells believes that GNL needs drastic corporate governance changes. In connection with the Annual Meeting, Blackwells has nominated two independent and highly qualified individuals for the GNL Board, Jim Lozier and Richard O’Toole. Both individuals bring a wealth of real estate and fiduciary experience, along with a track record of creating value. Blackwells has also proposed a series of advisory resolutions to bring much needed corporate governance reform to GNL. We believe these proposals, and our nominees, will bring integrity, intelligence and best practices of corporate governance to GNL once and for all.

Your vote is very important. In response to Blackwells’ nominations, the GNL Board has engaged in costly litigation to shield itself from scrutiny and suppress the voice of its shareholders. We urge all our fellow shareholders to vote.

Shareholders should use the WHITE Universal Proxy Card to vote FOR all of Blackwells’ director nominees. We are also asking you to vote FOR each of the Blackwells’ non-binding advisory resolutions on the WHITE Universal Proxy Card.

If you have already voted on the Company’s proxy card, you have every right to change your vote by (i) signing, dating and returning a later dated WHITE Universal Proxy Card, (ii) voting via the Internet, by following the instructions on the WHITE Universal Proxy Card or (iii) voting virtually at the Annual Meeting.

We thank our fellow shareholders for their support and look forward to finally putting an end to the ongoing value destruction at GNL.

Shareholders who require assistance voting their WHITE Universal Proxy Card can contact Morrow Sodali at 1-800-662-5200 or at [email protected].

Sincerely,

Jason Aintabi

Chief Investment Officer

Blackwells Capital

About Blackwells Capital

Blackwells Capital was founded in 2016 by Jason Aintabi, its Chief Investment Officer. Since that time, it has made investments in public securities, engaging with management and boards, both publicly and privately, to help unlock value for stakeholders, including shareholders, employees and communities. Blackwells’ investments in real estate have ranged from property development and management to REITs and adjacent real estate activities, including financing, origination, and managing real estate backed securities, including direct mezzanine and equity investments. Throughout their careers, Blackwells’ principals have invested globally on behalf of leading public and private equity firms and have held operating roles and served on the boards of media, energy, technology, insurance and real estate enterprises. For more information, please visit www.blackwellscap.com.

IMPORTANT ADDITIONAL INFORMATION

Blackwells Onshore I LLC, Blackwells, Related Fund Management, LLC, Jason Aintabi, Richard O’Toole and James L. Lozier (collectively, the “GNL Participants”) are participants in the solicitation of proxies from the shareholders of GNL in connection with the 2023 annual meeting of shareholders (including any other meeting of shareholders held in lieu thereof, and adjournments, postponements, reschedulings or continuations thereof, the “2023 GNL Annual Meeting”). The GNL Participants have filed with the Securities and Exchange Commission (the “SEC”) a definitive proxy statement and accompanying WHITE universal proxy card to be used in connection with any such solicitation of proxies from GNL’s shareholders for the 2023 GNL Annual Meeting. BLACKWELLS STRONGLY ADVISES ALL SHAREHOLDERS OF GNL TO READ THE DEFINITIVE PROXY STATEMENT, THE ACCOMPANYING WHITE UNIVERSAL PROXY CARD AND OTHER DOCUMENTS RELATED TO THE SOLICITATION OF PROXIES BY THE GNL PARTICIPANTS AS THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ADDITIONAL INFORMATION RELATED TO THE GNL PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE. The definitive proxy statement and an accompanying WHITE universal proxy card will be furnished to some or all of GNL’s shareholders and will be, along with other relevant documents, available at no charge on the SEC’s website at http://www.sec.gov/. Requests for copies should be directed to Blackwells Onshore I LLC.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230418006119/en/

Gagnier Communications

Dan Gagnier

646-569-5897

[email protected]

Longacre Square Partners

[email protected]

646-386-0091

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: REIT Finance Professional Services Commercial Building & Real Estate Construction & Property

MEDIA:

Logo

Senseonics Announces the First Pediatric Study Participant Insertions in the ENHANCE Clinical Trial

GERMANTOWN, Md.–(BUSINESS WIRE)–
Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the first pediatric study participant has been inserted with Eversense® 365-day system as part of the pivotal ENHANCE clinical trial at the AMCR Institute, a clinical research center focused on pre-diabetes, type 1, type 2 diabetes and obesity, under the direction of Dr. Timothy Bailey.

“It is a priority for Senseonics to extend the benefits of Eversense to the pediatric patient population. Positive results in the trial would support expanding our ability to transform lives in the global diabetes community,” said Francine Kaufman, M.D., Chief Medical Officer of Senseonics. “The differentiated features of our long-term implantable Eversense system are uniquely suited to benefit pediatrics and enable parents and their children to work together to manage diabetes. Young people would have the ability to remove their transmitters to participate in activities, without having to worry about wasting valuable sensors, and enjoy ring-free vibrating alarms to help manage their sugar levels without attracting unwanted attention to themselves.”

“I am excited to be one of the investigators in the ENHANCE Trial and thrilled to be the first to enroll subjects in the pediatric extension,” said Timothy Bailey, M.D., head of AMCR Institute in Escondido, California. “In our experience, CGM is an essential tool for all people with diabetes, especially for those who take insulin. We believe having additional accurate, and especially long-term wear, CGM options for our pediatric patients and their families will increase utilization of the technology and improve the quality of their lives.”

The ENHANCE Trial is designed to evaluate the accuracy and safety of the Eversense system for up to one year. Over 165 adult subjects were inserted with Eversense systems in four centers across the United States. Enrollment for the 365-day sensor configuration was completed in September 2022 and the last patient is expected to complete their 365-day visit during the third quarter of 2023. Data gathered in this trial is also planned to be used to submit for the integrated continuous glucose monitoring, iCGM, designation in 2023. An investigational device exemption (“IDE”) supplement was submitted and approved for expansion of the trial to allow for pediatric patients 14 to 18 years of age and the first pediatric study participants were enrolled in Q2 2023.

About Senseonics

Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM systems, Eversense®, Eversense® XL and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.

About Eversense

The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 years and older with diabetes for up to 6 months. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a trained and certified health care provider. The Eversense CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see https://www.ascensiadiabetes.com/eversense/safety-info/.

Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for Senseonics, including statements about expanding the benefits of Eversense to additional populations, statements regarding patient perceptions of the benefits of Eversense, statements regarding user adoption of Eversense, statements regarding advancing development programs, statements regarding regulatory submissions, and other statements containing the words “believe,” “expect,” “intend,” “may,” “projects,” “will,” “planned,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the commercial launch of Eversense® E3 CGM system and commercial expansion of the Eversense product, uncertainties inherent in the transition of commercialization responsibilities to Ascensia Diabetes Care and its commercial initiatives, uncertainties inherent in collaborating with a new partner in the Nurse Practitioner Group and that partner’s assumption of certain clinical and administrative activities, uncertainties in insurer, regulatory and administrative processes and decisions, uncertainties in the duration and severity of the COVID-19 pandemic, uncertainties inherent in the development and registration of new technology, uncertainties relating to the current economic environment, and such other factors as are set forth in the risk factors detailed in Senseonics’ Annual Report on Form 10-K for the year ended December 31, 2022 and Senseonics’ other filings with the SEC under the heading “Risk Factors.” In addition, the forward-looking statements included in this press release represent Senseonics’ views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics’ views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics’ views as of any date subsequent to the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230418006149/en/

INVESTOR CONTACT

Philip Taylor

Gilmartin Group

415-937-5406

[email protected]

KEYWORDS: Maryland United States North America

INDUSTRY KEYWORDS: Diabetes Health Clinical Trials Medical Devices

MEDIA:

Logo

JBG SMITH Announces Date of First Quarter 2023 Results

BETHESDA, Md.–(BUSINESS WIRE)–
JBG SMITH (NYSE: JBGS), a leading owner and developer of high-quality, mixed-use properties in the Washington, DC market, today announced that it will report first quarter 2023 financial results after the close of trading on May 9, 2023. The Company’s quarterly investor package, including its earnings release, will be available in the Investor Relations section of its website at investors.jbgsmith.com.

About JBG SMITH

JBG SMITH owns, operates, invests in, and develops mixed-use properties in high growth and high barrier-to-entry submarkets in and around Washington, DC. Through an intense focus on placemaking, JBG SMITH cultivates vibrant, amenity-rich, walkable neighborhoods throughout the Washington, DC metropolitan area. Approximately two-thirds of JBG SMITH’s holdings are in the National Landing submarket in Northern Virginia, which is anchored by four key demand drivers: Amazon’s new headquarters, which is being developed by JBG SMITH; Virginia Tech’s under-construction $1 billion Innovation Campus; the submarket’s proximity to the Pentagon; and JBG SMITH’s deployment of next-generation public and private 5G digital infrastructure. JBG SMITH’s dynamic portfolio currently comprises 15.3 million square feet of high-growth office, multifamily, and retail assets at share, 98% of which are metro-served. It also maintains a development pipeline encompassing 9.7 million square feet of mixed-use development opportunities. JBG SMITH’s capital allocation strategy is to shift the majority of its portfolio to multifamily and concentrate its office assets in National Landing. JBG SMITH is committed to the operation and development of green, smart, and healthy buildings and plans to maintain carbon neutral operations annually. For more information on JBG SMITH please visit www.jbgsmith.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230418005937/en/

Barbat Rodgers

JBG SMITH

Senior Vice President, Investor Relations

(240) 333-3805

[email protected]

KEYWORDS: Maryland United States North America

INDUSTRY KEYWORDS: Residential Building & Real Estate Commercial Building & Real Estate Urban Planning Construction & Property

MEDIA:

Logo